Skip to content
Open access

Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease

Jul 2026 · Alzheimer's & Dementia · Vol 12 · 0 citations · 44 references
Medicine

TL;DR

Lower baseline C3 was consistently associated with ARIA risk across sensitivity analyses and higher baseline C1q with smaller amyloid reduction at week 26, and this association persisted in international normalized ratio (INR)‐adjusted and simplified models.

Abstract

Abstract INTRODUCTION The classical complement cascade has been implicated in amyloid beta (Aβ) clearance and in the pathogenesis of amyloid‐related imaging abnormalities (ARIA) during anti‐amyloid monoclonal antibody therapy. Clinically accessible peripheral biomarkers of this cascade remain uncharacterized in real‐world cohorts.

Methods

We conducted a retrospective, hypothesis‐generating cohort study of 62 patients with early Alzheimer's disease initiating lecanemab. ARIA risk was evaluated in the safety cohort (N = 62), and absolute amyloid reduction at week 26 was evaluated in the efficacy cohort with paired baseline and 26‐week amyloid positron emission tomography (N = 34). Associations of baseline plasma C1q, C3, and apolipoprotein E ε4 (APOE ε4) carrier status with these outcomes were examined using Firth's penalized logistic regression and bootstrap linear regression (2000 iterations), with prespecified sensitivity analyses. Within‐subject changes in C3 (N = 30) and C1q (N = 19) were assessed by paired Wilcoxon test.

Results

Lower baseline C3 was nominally associated with higher ARIA risk (odds ratio [OR] per 1 SD = 0.44, 95% CI: 0.15 to 0.97, p = 0.040, uncorrected), and this association persisted in international normalized ratio (INR)‐adjusted and simplified models. C3 ≤ 25th percentile (≤99 mg/dL) showed a trend (OR: 4.78, 95% CI: 0.98 to 26.34, p = 0.052). In the efficacy cohort, higher baseline C1q was associated with smaller amyloid reduction (β = −6.86, 95% CI: −12.19 to −3.06, p = 0.002); carriers of at least one APOE ε4 allele, a status that in this cohort jointly reflects genotype and dose‐titration, showed less amyloid reduction (β = −19.50, 95% CI −31.57 to −8.40, p < 0.001). Within‐subject changes in C1q and C3 were not significant (p = 0.248 and 0.114, respectively).

Discussion

Lower baseline C3 was consistently associated with ARIA risk across sensitivity analyses and higher baseline C1q with smaller amyloid reduction at week 26. Findings are exploratory given the limited single‐center sample.

Read PDF

Similar papers

Review Open access Aug 2026

Fluid and Imaging Biomarkers in Lecanemab Therapy for Early Alzheimer’s Disease: Current Evidence, ARIA Risk Prediction, and Treatment Monitoring

Background/Objectives: Lecanemab, a humanized anti-amyloid-β protofibril antibody, achieves substantial amyloid clearance and modest slowing of clinical decline in early Alzheimer’s disease (AD). Amyloid-related imaging abnormalities (ARIA) represent the most clinically important safety concern, yet no fluid biomarker...

Pan-Woo Ko · 0 citations
Sep 2026

Validation of plasma core biomarkers of Alzheimer's disease: A multicenter study in usual practice conditions

Plasma p-tau217 is established as a first-choice biomarker for the early detection of AD pathology in specialized clinical settings, displaying excellent diagnostic accuracy and minimal site-related variability.

A. Sánchez-Soblechero, A. Villarejo, M. Carreras et al. · 0 citations
Open access Sep 2026

Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.

BACKGROUND Anti-amyloid antibodies slow cognitive and functional decline in individuals with early symptomatic Alzheimer's disease, but few studies have examined changes associated with these treatments in plasma biomarkers linked to neurodegeneration. We analysed changes in a panel of 130 plasma proteins and their ass...

Rui Mu, Anna Hofmann, Katherine Gong et al. · 1 citation
Open access Jul 2026

Lecanemab in symptomatic PSEN1 p.Met233Val early‐onset Alzheimer's disease: Neuroimaging safety, regional amyloid‐PET dynamics, and longitudinal plasma biomarkers

The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.

Min-Young Noh, Wonjae Sung, Hyunkee Kim et al. · 0 citations
Open access Sep 2026

Baseline CSF tau and short‐term clinical change during lecanemab therapy: A prospective real‐world cohort study in Japan

Abstract INTRODUCTION Real‐world prognostic evidence for cerebrospinal fluid (CSF) biomarkers during lecanemab therapy remains limited. We examined whether baseline CSF phosphorylated tau 181 (pTau181), total tau, and amyloid beta (Aβ) 42/Aβ40 were associated with 6‐month clinical change. METHODS This prospective singl...

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · 0 citations
Open access Sep 2026

Blood Amyloid-β Reduction Following Chongnoi-tang Treatment in Alzheimer’s Spectrum Conditions: A Retrospective Pilot Observational Study

Background/Objectives: Anti-amyloid immunotherapies reduce amyloid-β (Aβ) plaques but carry a 15–35% risk of amyloid-related imaging abnormalities (ARIA), particularly in APOE ε4/ε4 carriers. This preliminary observational study evaluated blood Aβ oligomer changes following treatment with the multi-component herbal for...

Jinhyuk Lee · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.